Olink

Olink®
Part of Thermo Fisher Scientific

Targeted proteomics in late-onset neonatal sepsis: an exploratory analysis

Pediatric Research, 2026

Schouten J., Kurul ?., Gorissen R., Reiss I., Willemsen S., Mazela J., Unger W., Simons S., Jans J., Taal H.

Disease areaApplication areaSample typeProducts
Immunological & Inflammatory Diseases
Infectious Diseases
Pediatrics
Patient Stratification
Plasma
Whole Blood In Vitro
Olink Target 96

Olink Target 96

Olink Explore 3072/384

Olink Explore 3072/384

Abstract

Background
Late-onset neonatal sepsis (LONS) is a major cause of morbidity and mortality in preterm infants, but early diagnosis remains difficult. We aimed to identify candidate proteomic biomarkers of LONS and evaluate whether these changes could be reproduced by in vitro stimulation.

Methods
Longitudinal blood samples were collected from preterm neonates with suspected LONS and non-septic controls in two neonatal intensive care units, at onset and after 24 and 48 hours. In parallel, whole blood from preterm neonates without LONS was stimulated in vitro with E. coli and S. epidermidis. Protein expression was quantified using targeted proteomics.

Results
Fifteen neonates with LONS, eight controls, and ten in vitro stimulation samples were included. Sixty-six proteins showed altered expression during LONS. Upregulated proteins were predominantly cytokines and chemokines, whereas downregulated proteins were associated with development, growth, and metabolism. Most alterations normalized within 48 hours. In vitro stimulation reproduced expression changes for a subset of proteins, suggesting direct pathogen-induced immune responses.

Conclusion
LONS in preterm neonates is associated with dynamic proteomic alterations. Combined clinical and in vitro analyses identified biologically relevant candidate biomarkers that may support future diagnostic and monitoring strategies. Further validation in larger, independent cohorts is required before clinical use.

Read publication ↗